Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Active, not recruiting · NCT03637543 · Registry updated 2026-05-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-05-08 | NCT03637543 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beth Israel Deaconess Medical Center | 161 |
| Bristol-Myers Squibb | 422 |
| Dana-Farber Cancer Institute | 324 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| DFCI Londonderry | Londonderry | United States | 1 |
| DFCI South Shore | South Weymouth | United States | 1 |
| St. Elizabeth's Medical Center | Boston | United States | 6 |